• Explore /
  • Poster
  • / Second-line therapies in patients with <em>KRAS</em> wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.

Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.

Abstract Poster

Authors

null

Dominik Paul Modest

Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany

Dominik Paul Modest , Sebastian Stintzing , Ludwig Fischer Von Weikersthal , Thomas Decker , Alexander Kiani , Ursula Vehling-Kaiser , Salah-Eddin Al-Batran , Tobias Heintges , Christian A. Lerchenmuller , Christoph Kahl , Gernot Seipelt , Frank Kullmann , Martina Stauch , Werner Scheithauer , Swantje Held , Clemens Albrecht Giessen , Andreas Jung , Thomas Kirchner , Volker Heinemann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT00433927

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3558^)

DOI

10.1200/jco.2014.32.15_suppl.3558

Abstract #

3558^

Poster Bd #

21

Abstract Disclosures

Similar Posters

First Author: Scott Kopetz

First Author: Mitsukuni Suenaga

First Author: Akihito Tsuji

First Author: Tomohiro Kondo